C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of sunitinib in patients from Italy with metastatic renal cell carcinoma: final results from an expanded-access trial.
Cora N. Sternberg,Fabio Calabrò,Sergio Bracarda,Giacomo Cartenì,Giovanni Lo Re,Enzo Maria Ruggeri,Umberto Basso,Giampietro Gasparini,Libero Ciuffreda,Vittorio Ferrari,Andrea Bonetti,E. Fea,Donatello Gasparro,Davide Tassinari,Roberto Labianca,Cristina Masini,Kolette D. Fly,Ke Zhang,Subramanian Hariharan,Barbara Capaccetti,Camillo Porta +20 more
TL;DR: In a large population of Italian mRCC patients, sunitinib had a manageable safety profile and encouraging efficacy and here, the efficacy and safety results for the EAP subpopulation in Italy are reported.
Journal ArticleDOI
Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
TL;DR: The safety and tolerability of pazopanib for locally advanced/metastatic RCC is outlined, and the toxicity profile is comparable, but in some ways distinct, from other antiangiogenic drugs used in the treatment of RCC.
Journal ArticleDOI
The Contemporary Role of Chemotherapy for Advanced Testis Cancer: A Systematic Review of the Literature
Fabio Calabrò,Peter Albers,Carsten Bokemeyer,Chris Martin,Lawrence H. Einhorn,Alan Horwich,Susanne Krege,Hans-Joachim Schmoll,Cora N. Sternberg,Gedske Daugaard +9 more
TL;DR: The routine use of high-dose chemotherapy in patients with intermediate- or poor-prognosis GCT has not improved treatment outcome, but the role of tumour marker decline during the first cycles may provide useful prognostic information.
Journal ArticleDOI
Genomic Testing in Patients with Metastatic Castration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians
Axel S. Merseburger,Nick Waldron,Maria J. Ribal,Axel Heidenreich,Sven Perner,Karim Fizazi,Cora N. Sternberg,Joaquin Mateo,Manfred P. Wirth,Elena Castro,David Olmos,Daniel P. Petrylak,Simon Chowdhury +12 more
TL;DR: Genomic testing for mCRPC may provide information on prognostic, predictive, and resistance biomarkers and routine genomic testing of men with advanced PC is recommended to guide management and treatment decisions.
Journal ArticleDOI
Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort.
Giuseppe Fornarini,Sara Elena Rebuzzi,Giuseppe Luigi Banna,Fabio Calabrò,G. Scandurra,U. De Giorgi,Cristina Masini,Cinzia Baldessari,Emanuele Naglieri,Claudia Caserta,S. Manacorda,Marco Maruzzo,M. Milella,Consuelo Buttigliero,R. Tambaro,P. Ermacora,Franco Morelli,Franco Nolè,C. Astolfi,Cora N. Sternberg +19 more
TL;DR: The SAUL trial as mentioned in this paper investigated the safety and efficacy of atezolizumab in a real-world setting on 1004 patients with locally advanced or metastatic urothelial carcinoma who progressed to one to three prior systemic therapies.